Bioniz has secured $13m in a round co-led by Takeda Ventures and David Pyott, who has been named chairman of the immuno-inflammatory disease drug developer.
Takeda Ventures, the investment arm of pharmaceutical firm Takeda, co-led a $13m series A round yesterday for US-based biopharmaceutical company Bioniz Therapeutics.
David Pyott, former CEO of medical device company Allergan, co-led the round and has been appointed as chairman of Bioniz’s board. Cota Capital and angel investor Joe Kiani, the chairman and chief executive of medical device company Masimo, also supplied funding.
Established in 2010, Bioniz is working on treatments for immuno-inflammatory diseases. Its lead candidate, BNZ-1, targets associated…
